HLA-C and neoplasm: Low expression levels of the MHC class II transporter and antigen presenting gene CD74 in TAS as compared to tumor of BA vs WA PCa patients may suggest a reduced tumor antigen presentation in TAS in BA patients, as class II MHC processing and regulation cannot properly occur in the absence of CD74 [44].